2018
DOI: 10.18632/oncotarget.24769
|View full text |Cite
|
Sign up to set email alerts
|

Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort

Abstract: BackgroundSorafenib is the current standard of care for patients with advanced or metastatic hepatocellular carcinoma. Currently no universally agreed model exists correlating the Neutrophil Lymphocyte ratio (NLR) and non-secretion of AFP with the survival of HCC patients treated with sorafenib.Patients and MethodsWe retrospectively analysed patient records with a confirmed diagnosis of HCC treated with sorafenib between April 2009 and March 2014. Survival analysis was performed using the Kaplan–Meier method a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
10
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(10 citation statements)
references
References 37 publications
0
10
0
Order By: Relevance
“…However, AFP levels also increase in pregnancy and some benign diseases such as severe hepatitis and cirrhosis. AFP is not significantly increased in about 35% ~ 40% of the HCC patients, especially for small HCC [ 6 , 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…However, AFP levels also increase in pregnancy and some benign diseases such as severe hepatitis and cirrhosis. AFP is not significantly increased in about 35% ~ 40% of the HCC patients, especially for small HCC [ 6 , 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…However, AFP levels also increase in pregnancy and some benign diseases such as severe hepatitis and cirrhosis. AFP is not signi cantly increased in about 35% ~ 40% of the HCC patients, especially for small HCC [3,4].…”
Section: Introductionmentioning
confidence: 90%
“…However, the levels of AFP were normal in 35-40% HCC patients, causing false negatives. Thus, EASL excluded AFP measurement from the guideline due to its insufficient diagnostic accuracy (61,62). In this context, serum biomarker PIVKA-II was emerging as a complementary tool for HCC surveillance.…”
Section: Clinical Relevance Of Pivka-ii In Hcc Surveillance For Hcc In High-risk Populationmentioning
confidence: 99%